Literature DB >> 19801494

Type 1 diabetic cardiomyopathy in the Akita (Ins2WT/C96Y) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function.

Ratnadeep Basu1, Gavin Y Oudit, Xiuhua Wang, Liyan Zhang, John R Ussher, Gary D Lopaschuk, Zamaneh Kassiri.   

Abstract

Diabetic cardiomyopathy is an important contributor to diastolic and systolic heart failure. We examined the nature and mechanism of the cardiomyopathy in Akita (Ins2(WT/C96Y)) mice, a model of genetic nonobese type 1 diabetes that recapitulates human type 1 diabetes. Cardiac function was evaluated in male Ins2WT/C96Y and their littermate control (Ins2WT/WT) mice using echocardiography and tissue Doppler imaging, in vivo hemodynamic measurements, as well as ex vivo working heart preparation. At 3 and 6 mo of age, Ins2WT/C96Y mice exhibited preserved cardiac systolic function compared with Ins2WT/WT mice, as evaluated by ejection fraction, fractional shortening, left ventricular (LV) end-systolic pressure and maximum rate of increase in LV pressure in vivo, cardiac work, cardiac power, and rate-pressure product ex vivo. Despite the unaltered systolic function, Ins2WT/C96Y mice exhibited significant and progressive diastolic dysfunction at 3 and 6 mo of age compared with Ins2WT/WT mice as assessed by tissue and pulse Doppler imaging (E-wave velocity, isovolumetric relaxation time) and by in vivo hemodynamic measurements (LV end-diastolic pressure, time constant of LV relaxation, and maximum rate of decrease in LV pressure). We found no evidence of myocardial hypertrophy or fibrosis in the Ins2WT/C96Y myocardium. Consistent with the lack of fibrosis, expression of procollagen-alpha type I, procollagen-alpha type III, and fibronectin were not increased in these hearts. Ins2WT/C96Y hearts showed significantly reduced sarcoplasmic reticulum Ca2+-ATPase 2a (cardiac sarcoplasmic reticulum Ca2+ pump) levels, elevated beta-myosin heavy chain isoform, increased long-chain fatty acids, and triacylglycerol with evidence of lipotoxicity, as indicated by a significant rise in ceramide, diacylglycerol, and lipid deposits in the myocardium. Consistent with metabolic perturbation, and a switch to fatty acid oxidation from glucose oxidation in Ins2WT/C96Y hearts, expression of mitochondrial long-chain acyl-CoA dehydrogenase and pyruvate dehydrogenase kinase isoform 4 were increased. Insulin treatment reversed the diastolic dysfunction, the elevated B-type natriuretic peptide and beta-myosin heavy chain, and the reduced sarcoplasmic reticulum Ca2+-ATPase 2a levels with abolition of cardiac lipotoxicity. We conclude that early type 1 diabetic cardiomyopathy is characterized by diastolic dysfunction associated with lipotoxic cardiomyopathy with preserved systolic function in the absence of interstitial fibrosis and hypertrophy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19801494     DOI: 10.1152/ajpheart.00452.2009

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  84 in total

1.  Decreased Mitochondrial Pyruvate Transport Activity in the Diabetic Heart: ROLE OF MITOCHONDRIAL PYRUVATE CARRIER 2 (MPC2) ACETYLATION.

Authors:  Shraddha S Vadvalkar; Satoshi Matsuzaki; Craig A Eyster; Jennifer R Giorgione; Lee B Bockus; Caroline S Kinter; Michael Kinter; Kenneth M Humphries
Journal:  J Biol Chem       Date:  2017-02-01       Impact factor: 5.157

2.  Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats.

Authors:  Annayya R Aroor; James R Sowers; Shawn B Bender; Ravi Nistala; Mona Garro; Irina Mugerfeld; Melvin R Hayden; Megan S Johnson; Muhammad Salam; Adam Whaley-Connell; Vincent G Demarco
Journal:  Endocrinology       Date:  2013-05-07       Impact factor: 4.736

3.  Lactosylceramide contributes to mitochondrial dysfunction in diabetes.

Authors:  Sergei A Novgorodov; Christopher L Riley; Jin Yu; Jarryd A Keffler; Christopher J Clarke; An O Van Laer; Catalin F Baicu; Michael R Zile; Tatyana I Gudz
Journal:  J Lipid Res       Date:  2016-02-21       Impact factor: 5.922

4.  Early activation of matrix metalloproteinases underlies the exacerbated systolic and diastolic dysfunction in mice lacking TIMP3 following myocardial infarction.

Authors:  Vijay Kandalam; Ratnadeep Basu; Thomas Abraham; Xiuhua Wang; Ahmed Awad; Wei Wang; Gary D Lopaschuk; Nobuyo Maeda; Gavin Y Oudit; Zamaneh Kassiri
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-07-30       Impact factor: 4.733

5.  Retinal blood flow abnormalities following six months of hyperglycemia in the Ins2(Akita) mouse.

Authors:  William S Wright; Amit Singh Yadav; Robert M McElhatten; Norman R Harris
Journal:  Exp Eye Res       Date:  2012-03-13       Impact factor: 3.467

6.  Diastolic dysfunction is associated with cardiac fibrosis in the senescence-accelerated mouse.

Authors:  Alana L Reed; Atsuko Tanaka; Dan Sorescu; Hong Liu; Euy-Myoung Jeong; Megan Sturdy; Erik R Walp; Samuel C Dudley; Roy L Sutliff
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-07-01       Impact factor: 4.733

7.  Hyperglycemia-Driven Inhibition of AMP-Activated Protein Kinase α2 Induces Diabetic Cardiomyopathy by Promoting Mitochondria-Associated Endoplasmic Reticulum Membranes In Vivo.

Authors:  Shengnan Wu; Qiulun Lu; Ye Ding; Yin Wu; Yu Qiu; Pei Wang; Xiaoxiang Mao; Kai Huang; Zhonglin Xie; Ming-Hui Zou
Journal:  Circulation       Date:  2019-04-16       Impact factor: 29.690

Review 8.  Animal models of insulin resistance and heart failure.

Authors:  Mauricio Velez; Smita Kohli; Hani N Sabbah
Journal:  Heart Fail Rev       Date:  2014-01       Impact factor: 4.214

9.  MicroRNA-133a regulates DNA methylation in diabetic cardiomyocytes.

Authors:  Vishalakshi Chavali; Suresh C Tyagi; Paras K Mishra
Journal:  Biochem Biophys Res Commun       Date:  2012-07-27       Impact factor: 3.575

10.  Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol.

Authors:  Paras K Mishra; Neetu Tyagi; Utpal Sen; Irving G Joshua; Suresh C Tyagi
Journal:  Cardiovasc Diabetol       Date:  2010-09-09       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.